been granted registration during the last three years alongwith the name of the bulk drug on which each of the formulation is based;

(b) whether the bulk drug concerned is imported or indigenous;

(c) names of the formulations which have already been marketed by these companies;

(d) what are the details of ratio-parameter of each company at present and what was the ex-factory value of production of bulk drugs and formulations separately during the last three years, year-wise; and

(e) whether any of these companies have commenced production of any of bulk drug during the last three years; if so, details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) (b) and (e) Details of Industrial Approvals granted from time to time to non-FERA companies are published regularly by the India Investment Centre in their Monthly News Letter. Copies of this publication are available in the Parliament Library.

Under the existing Drug Policy, non-FERA companies are not required to produce their own bulk drugs for manufacturing formulations.

(c) My Ministry does not monitor the production/marketing of formulations by individual companies.

(d) For non-FERA companies the ratio between the value of bulk drug production and value of formulation production should be 1:10. DGTD registration for formulations have been granted only if a company fulfils the aforesaid ratio-parameters.

Reduced production by M/s. Pfizer

559. SHRIMATI MAIMOONA SULTAN: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is fact that Pfizer has deliberately reduced the production of an effective Anti-TB drug PAS and its Salts;

(b) if so, what is the licensed capacity of this company for the production of PAS and its Salts and what was the production of this drug of this company during the last three years, year-wise;

(c) what steps have been taken by Government in this direction;

(d) whether it is also a fact that this company is over-charging the prices of many of their products and have not implemented the fixed prices; and

(e) names of those products and what was the sales turn-over of those products during the last three years year-wise?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (c) Production of PAS in the country has been decreasing mainly because of replacement by more recent anti-TB drugs like Ethambutol.

(b) M/s. Pfizer are licensed to produce 110 tons/annum of PAS and its salts. Production of this bulk drug by the company was as under:—

Year	Production (Tons.)
1982-83 . . .	12·60
1983-84 . . .	3.67
1984-85 . . .	8.52

(d) and (e) M/s. Pfizer Ltd. are marketing formulations based on Oxytetracycline and PAS and its salts at the prices allowed by the Delhi High Court through its judgment delivered on 17th December, 1984. Government have filed a special leave petition in the Supreme Court against the judgment of the Delhi High Court. The Company

was also marketing multi-vitamin formulations at prices based on a judgment of the Bombay High Court. The Prices of these formulations were re-fixed in March, 1986 under the Drugs (Prices Control) Order, 1979. Sales turnover of individual formulations is not monitored.

Import of Bulk Drugs

560. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to state:

(a) what is the total value of import of bulk drugs, drug intermediates and other raw materials during the last three years, year-wise, of Glaxo, Merck Sharp and Dhome, Infar, Pfizer, Hochest and German Remedies;

(b) whether it is a fact that the bulk drugs imported are being produced by their principals in their own country from basic stages;

(c) the names of drug intermediates being imported by each of these companies during the last three years, year-wise;

(d) whether it is a fact that the technology for the bulk drugs being imported by them as well as the drug intermediates for the production of bulk drugs is available with their principals; and

(e) if so, what are the reasons that these companies are not being directed to produce these bulk drugs from basic stages in the country?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (c) Company-wise imports are not being monitored by this Ministry.

(b) and (d) The desired information is not available.

(e) Drugs are produced by these companies as per the industrial licences granted to them.

Electronic Mail Despatch System

561. SHRI SURESH KALMADI: SHRI DHARAM CHANDER PRASHANT:

Will the Minister of COMMUNICATIONS be pleased to state:

(a) whether it is a fact that electronic mail despatch system is proposed to be introduced by the Postal Department; and

(b) if so, what are the details in this regard?

THE MINISTER OF STATE OF THE MINISTRY OF COMMUNICATIONS AND THE MINISTER OF STATE IN THE MINISTRY OF HOME AFFAIRS (SHRI RAM NIWAS MIRDHA): (a) A proposal for introduction of Electronic Mail Service is under consideration.

(b) The details of the proposal have not been fully worked out as yet.

High-Level Apex Committee for Developing Petro-chemical Industry

562. SHRI N.E. BALARAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether a high-level apex Committee has been constituted to formulate a long term integrated plan for the growth of the petro-chemical industry; and

(b) if so, the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) Yes, Sir. An Apex Committee, has been set up in April, 1986 in the Department of Chemicals & Petro-chemicals to formulate a long-term integrated growth oriented plan for petro-chemical industry. The Apex Committee, to be assisted by four sub-groups on Hydrocarbon, Polymer, Synthetic Fibres including intermediates and other petrochemicals, is headed by Secretary (C&PC).